

CERTIFICATE OF MAILING

Im

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 11, 2004

Name of Person Mailing: <u>Joan Mazzeo</u>
Signature: <u>Joan Mazzeo</u>

**The Company of the Company of

Date: August 11, 2004

PATENTS Attorney Docket No. 01-0157-CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Elzein et al.)	Examiner: not assigned
)	
Serial No. 10/722,702)	Group Art Unit 1623
)	
Filed: November 25, 2003)	

For: ADENOSINE RECEPTOR A3 AGONISTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Submission of Replacement Declaration and Power of Attorney

Enclosed please find one (1) replacement Declaration and Power of Attorney in support of the above-referenced patent application. Should there be any questions regarding this submission of this document, please contact the undersigned attorney at (650) 384-8755.

Respectfully submitted,

August 11, 2004

Date

/s/ Elin Hartrum

Attorney for Applicants

Reg. No. 43,663



COMBINED DECLARATION AND POWER OF ATTORNEY FOR CONTINUATION-IN-PART PATENT APPLICATION

AND COM-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Adenosine A3 Receptor Agonists, the patent application on which:

is attached hereto.	
was filed on 25-Nov-2003 and assigned Serial No.	10/722,702.

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge and understand that I am an individual who has a duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations §§ 1.56(a) and (b) which state:

- "(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) it refutes, or is inconsistent with, a position the applicant takes in:
 - (i) opposing an argument of unpatentability relied on by the Office, or
 - (ii) asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability."

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application. This invention was not in public use or on sale in the United States of America more than one year prior to this application. This invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than one year prior to this application.

I hereby claim the benefit under Title 35, United States Code § 120 of any patent application(s) listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations § 1.56(a) and (b) set forth above which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status (patented, pending, abandoned)
10/212,896	05-Aug-2002	Abandoned

I hereby appoint the following attorneys and agents to prosecute that application and to transact all business in the Patent and Trademark Office connected therewith and to file, to prosecute, and to transact all business in connection with all patent applications directed to the invention:

Brian Lewis, Reg. No. 32,502 Pauline Clarke, Reg. No. 29,783 J. Elin Hartrum, Reg. No. 43,663 CUSTOMER NO. 27716 Address all correspondence and telephone calls to Brian Lewis, Registration No. 32,502, at:

CV Therapeutics, Inc.
Patent Group
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8500 Telephone
(650) 475-0359 Facsimile

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Elfatih Elzein			
Inventor's signature Sydul 4 Date: 4115104			
Residence: 4644 Creekwood Drive Fremont, California 94555			
Citizenship: Sudan			
Post Office Address: 4644 Creekwood Drive Fremont, California 94555			
Full name of second joint inventor: Venkata Palle			
Inventor's signature Date:			
Residence: D-011, Oakwood Estate, Akash Neem Marg, DLF, Phase II, Gurgoan, India 122001			
Citizenship: United States			
Post Office Address: D-011, Oakwood Estate, Akash Neem Marg, DLF, Phase II, Gurgoan,			
India 122001			
Full name of third joint inventor: Vaibhav Varkhedkar			
Tun name of time joint inventor. Valoriav Varkietikar			
Inventor's signature Date:			
Inventor's signature Date:			
Inventor's signature Date:			
Inventor's signature Date:			
Inventor's signature Date:			
Inventor's signature Date:			
Inventor's signature Date: Residence: 7655 Palmilla Drive, #4405, San Diego, California 92122 Citizenship: India Post Office Address: 7655 Palmilla Drive, #4405, San Diego, California 92122 Full name of fourth joint inventor: Jeff Zablocki			
Inventor's signature Date: Residence: 7655 Palmilla Drive, #4405, San Diego, California 92122 Citizenship: India Post Office Address: 7655 Palmilla Drive, #4405, San Diego, California 92122 Full name of fourth joint inventor: Jeff Zablocki Inventor's signature:			
Inventor's signature Date: Residence: 7655 Palmilla Drive, #4405, San Diego, California 92122 Citizenship: India Post Office Address: 7655 Palmilla Drive, #4405, San Diego, California 92122 Full name of fourth joint inventor: Jeff Zablocki			

Address all correspondence and telephone calls to Brian Lewis, Registration No. 32,502, at:

CV Therapeutics, Inc.
Patent Group
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8500 Telephone
(650) 475-0359 Facsimile

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Effatin Efzein		
Inventor's signature	Date:	
Residence: 4644 Creekwood Drive Fremont, California 94555		
Citizenship: Sudan		
Post Office Address: 4644 Creekwood Drive Fremont, California	94555	
Full name of second joint inventor: Venkata Palle		
Inventor's signature	Date:	
Residence: D-011, Oakwood Estate, Akash Neem Marg, DLF, Ph	ase II, Gurgoan, India 122001	
Citizenship: United States	DIE Dhees II Curses	
Post Office Address: D-011, Oakwood Estate, Akash Neem Marg India 122001	g, DLF, Phase II, Gurgoan,	
IIIdia 122001		
Full name of third joint inventor: Vaibhav Varkhedkar		
Inventor's signature 1.M. Makhedbas	OFLIRIOU	
Residence: 7655 Palmilla Drive, #4405, San Diego, California 92122		
Citizenship: India		
Post Office Address: 7655 Palmilla Drive, #4405, San Diego, California 92122		
Full name of fourth joint inventor: Jeff Zablocki		
•		
Inventor's signature:	Date:	
Residence: 580 Sleeper Ave., Mountain View, California 94040		
Citizenship: United States of America		
Post Office Address: 580 Sleeper Ave., Mountain View, California 94040		

Address all correspondence and telephone calls to Brian Lewis, Registration No. 32,502, at:

CV Therapeutics, Inc.
Patent Group
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8500 Telephone
(650) 475-0359 Facsimile

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Elfatih Elzein		
Inventor's signature	Date:	
Citizenship: Sudan		
Post Office Address: 4644 Creekwood Drive Fremont, California	94555	
Full name of second joint inventor: Venkata Palle		
Inventor's signature fill Advangus	Date: April 27, 2004	
Residence: D-011, Oakwood Estate, Akash Neem Marg, DLF, Ph	ase II, Gurgoan, India 122001	
Citizenship: United States		
Post Office Address: D-011, Oakwood Estate, Akash Neem Marg	, DLF, Phase II, Gurgoan,	
India 122001		
Full name of third joint inventor: Vaibhav Varkhedkar		
Inventor's signature	Date:	
Residence: 7655 Palmilla Drive, #4405, San Diego, California 92	122	
Citizenship: India		
Post Office Address: 7655 Palmilla Drive, #4405, San Diego, California 92122		
Full name of fourth joint inventor: Jeff Zablocki		
Inventor's signature:	Date:	
Residence: 580 Sleeper Ave., Mountain View, California 94040		
Citizenship: United States of America		
Post Office Address: 580 Sleeper Ave., Mountain View, Californi	a 94040	